Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + degarelix
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Ipilimumab + degarelix is a combination therapy being investigated by Memorial Sloan Kettering Cancer Center for the treatment of early-stage prostate cancer. Ipilimumab is a fully human monoclonal antibody that inhibits Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), a checkpoint molecule that normally suppresses T-cell activation; by blocking CTLA-4, ipilimumab enhances the immune system's ability to recognize and destroy cancer cells. Degarelix is a synthetic peptide and gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly suppresses testosterone production, a key driver of prostate cancer growth. The combination is specifically being evaluated in a Phase 2 clinical trial (NCT02020070) for men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) or biochemically recurrent prostate cancer, often in conjunction with radical prostatectomy, to determine if early intervention with dual hormonal and immune therapy can improve clinical outcomes before the disease progresses to a castration-resistant state.
- Other names
- ipilimumab + degarelixMDX-010MDX010MDX 010BMS-734016BMS734016BMS 734016FE200486FE-200486FE 200486
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on ipilimumab + degarelix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + degarelix.